Hodgkin Lymphoma
Therapeutic response
Precision oncology relationships for therapeutic response involving this cancer type.
| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin, Dacarbazine, Doxorubicin, Vinblastine | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin, Cisplatin, Cytarabine, Etoposide | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Brentuximab vedotin | |
| Sensitivity (+) | CD30 +, HER2-negative | Hodgkin Lymphoma | Brentuximab vedotin, Carboplatin, Etoposide, Ifosfamide | |
| Sensitivity (+) | CD30 + | Hodgkin Lymphoma | Bendamustine, Brentuximab vedotin |